Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Chemo Effects May Outweigh Obesity-Related GI Alterations in Breast Cancer

April 11, 2025
By Roman Fabbricatore
Fact checked by" Russ Conroy
News
Article
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

Findings from the presentation revealed that among patients with and without obesity receiving chemotherapy for breast cancer, alpha- and beta-diversity analyses did not identify significant GI microbiome differences based on obesity.

Findings from the presentation revealed that among patients with and without obesity receiving chemotherapy for breast cancer, alpha- and beta-diversity analyses did not identify significant GI microbiome differences based on obesity.

The effects of obesity-related gastrointestinal (GI) microbiome alterations and their impact on symptom burden may be outweighed by the effects of chemotherapy in patients with breast cancer, according to findings from a poster presentation at the 50th Annual Oncology Nursing Society Conference.1

Findings from the presentation revealed that among patients with and without obesity receiving chemotherapy for breast cancer, alpha- and beta-diversity analyses did not identify significant GI microbiome differences based on obesity. Furthermore, no significant differences in symptom burden were observed between patients with and without obesity.

Additionally, least absolute shrinkage and selection operator (LASSO) analysis identified 8 bacteria significantly enriched in patients with breast cancer and obesity: Collinsella aerofacien, Prevotella 7, Coprobacillus cateniformis, Ruminococcus torques group, Agathobacter, Frisingicoccus, Roseburia inulinivorans, and Monoglobus pectinilyticus.

Functional analyses of these bacteria established that they were responsible for the severity of neurologic symptoms in patients with breast cancer, as well as pro-inflammatory effects in colorectal cancers. Additionally, the results from this study contrast with findings from a recent meta-analysis published in BMC Microbiology and Infectious Disease, which showed that patients with obesity saw a significant decrease in the richness and diversity of gut bacteria.2

“Identifying biologic mechanisms driving symptoms is necessary for the development of therapies to reduce cancer-related symptom burden,” Catherine Cherwin, PhD, RN, assistant professor of Nursing at the Iowa College of Nursing, wrote with study coinvestigators.1 “While obesity may alter the GI microbiome and influence symptom burden in women with breast cancer, these effects may be outweighed by the effects of chemotherapy on the gut.”

The study included women who were obese or not obese receiving taxane-based chemotherapy for breast cancer. Women were classified as obese if they had BMI of 30 or greater. Patients were recruited while receiving chemotherapy on the first day of a cycle at an outpatient chemotherapy clinic and provided a stool sample and symptom reports at 1 week following treatment.

Symptoms were assessed via the Memorial Symptom Assessment Scale (MSAS), which records the occurrence, frequency (1-4), severity (1-4), and distress of symptoms (0-4) of 32 possible symptoms in the week following chemotherapy. Symptom burden was analyzed as the average ratings for frequency, severity, and distress, as well as for individual symptoms. T-tests or Mann-Whitney U tests were used to compare symptom burden between patients with and without obesity.

The study was initiated to compare symptom reports and GI microbiome composition between obese vs non-obese populations with breast cancer to identify microbial influences for symptom severity. Historically, patients with obesity and breast cancer experienced higher symptom burden, reduced treatment efficacy, and increased mortality vs those who were not obese. Additionally, obesity is associated with changes in the GI microbiome, which has been shown to regulate gut health through the regulation of epithelial integrity, GI mucus degradation, and GI inflammation.

Among patients with breast cancer identified as obese (n = 26) and non-obese (n = 33), the average age was 57.96 years (SD, 11.34) vs 47.48 (SD, 13.03). Additionally, among the respective groups, the mean BMI was 35.44 (SD, 5.71) vs 25.07 (SD, 3.03), 81% vs 97% were White, and 96% vs 94% were non-Hispanic. Additionally, 62% vs 82% had stage I or II breast cancer.

Regarding symptom reports, among the respective groups, the mean symptom occurrence was 13.76 (SD, 7.88) vs 13.12 (SD, 5.21). The mean symptom frequency was 1.93 (SD, 0.36) vs 2.02 (SD, 0.43), and the mean symptom severity was 1.93 (SD, 0.36) vs 1.91 (SD, 0.40). Furthermore, the mean symptom distress was 1.65 (SD, 0.63) vs 1.74 (SD, 0.59) in the obese and non-obese groups, respectively.

References

  1. Cherwin C, Hoang J, Roberts E, Mangalam A. Gut microbiome and symptom burden in obese and non-obese women receiving chemotherapy for breast cancer. Presented at the 50th Annual Oncology Nursing Society Conference; April 9-13, 2025; Denver, CO. Poster RS67.
  2. Hu X, Yu C, He Y, et al. Integrative metagenomic analysis reveals distinct gut microbial signatures related to obesity. BMC Microbiol. 2024;24(119). doi:10.1186/s12866-024-03278-5
Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
Advertisement

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Ben Saylor
May 31st 2025
Article

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

Roman Fabbricatore
May 31st 2025
Article

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.


40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Angel Valladares;Caroline Tai;Joseph Imperato
May 31st 2025
Article
Related Content
Advertisement

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Ben Saylor
May 31st 2025
Article

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL

Roman Fabbricatore
May 31st 2025
Article

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL who were 65 or older or had comorbidities.


40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Angel Valladares;Caroline Tai;Joseph Imperato
May 31st 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.